American Journal of Surgical Pathology:
Best Practices Recommendations in the Application of Immunohistochemistry in the Prostate: Report From the International Society of Urologic Pathology Consensus Conference
Epstein, Jonathan I. MD*; Egevad, Lars MD, PhD†; Humphrey, Peter A. MD, PhD‡; Montironi, Rodolfo MD§; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group
*Departments of Pathology, Urology, and Oncology, The John Hopkins Medical Institutions, Baltimore, MD
‡Department of Pathology, Yale University School of Medicine, New Haven, CT
†Department of Oncology–Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
§Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy
Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group: Mahul B. Amin, Thomas M. Ulbright, David Grignon, Kiril Trpkov, Antonio Lopez-Beltran, Ming Zhou, Pedram Argani, Brett Delahunt, Daniel M. Berney, John R. Srigley, Satish K. Tickoo, Victor E. Reuter.
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Jonathan I. Epstein, MD, Departments of Pathology, Urology, and Oncology, The John Hopkins Medical Institutions, The Weinberg Building, Rm. 2242 40l N. Broadway Street, Baltimore, MD 21231 (e-mail: firstname.lastname@example.org).
The following are the International Society of Urological Pathology (ISUP) recommendations for the use of immunohistochemistry (IHC) in prostate specimens. Either high–molecular weight cytokeratin (34βE12 or CK5/6 or others) or p63 or a combination of the 2 with AMACR either in a double or triple cocktail is recommended for the workup of small foci of atypical glands suspicious for adenocarcinoma of the prostate (PCa). ERG is optional as it is present in only 40% to 50% of prostate cancers and also positive in high-grade prostatic intraepithelial neoplasia. In the setting of obvious carcinoma or benign glands, there is no justification to do basal cell stains and AMACR. If there is a Gleason score of 3+4=7 or a higher-grade cancer on at least 1 part, the workup of other parts with an atypical focus suspicious for Gleason score 3+3=6 cancer is not recommended. In the setting of Gleason score 4+3 or 4+4=8 cancer on at least 1 part, the extent of high-grade cancer could affect clinical treatment such that workup of other atypical possible high-grade cancer foci is justified. In the setting of Gleason score 4+3 or higher-grade cancer on at least 1 part, given that intraductal carcinoma in the vast majority of cases is considered extension of high-grade cancer into prostatic ducts and acini, it is not recommended in the setting of definitive invasive high-grade cancer that workup of additional cribriform lesions be pursued. In the setting of Gleason score 3+3 on at least 1 part, the number of positive cores and/or their location could possibly affect subsequent therapy in terms of suitability for active surveillance or focal therapy, such that unless one knows with certainty that it would not affect therapy, it is justified to perform an IHC workup of additional atypical foci. In the differential diagnosis of high-grade PCa versus urothelial carcinoma (UC), the primary option is to use prostate-specific antigen (PSA) as a first test to identify PCa and GATA3 to identify UC. If GATA3 is not available, then HMWCK and p63 can be used. If the tumor is PSA positive with intense staining and HMWCK and p63 negative, the findings are diagnostic of PCa. If the tumor is equivocal/weak/negative for PSA and negative/focal for p63 and HMWCK, then one needs to perform staining for P501S, NKX3.1, and GATA3. Some experts also include PAP in this second round of staining. If the tumor is negative for PSA and diffusely strongly positive for p63 and HMWCK, the findings are diagnostic of UC. If the tumor is negative for PSA and moderately to strongly positive for GATA3, it is diagnostic of UC. Laboratories should be encouraged to use GATA3 for UC and add P501S and NKX3.1 as prostate markers in addition to PSA, p63, and HMWCK. If GATA3, p501S, and NKX3.1 are not available in equivocal cases, the case should be sent out for consultation to laboratories with these antibodies. The article also covers the use of IHC in: (1) high-grade PCa versus bladder adenocarcinoma; (2) prostatic small cell carcinoma versus high-grade PCa; (3) metastatic carcinoma of unknown primary: rule out PCa; (4) nonspecific granulomatous prostatitis/xanthoma versus high-grade PCa; (5) adult prostate sarcoma versus sarcomatoid PCa; (6) colorectal adenocarcinoma versus high-grade PCa; and (7) prognostic IHC markers.
IMMUNOHISTOCHEMICAL PANEL FOR THE DIAGNOSIS OF LIMITED PROSTATE ADENOCARCINOMA ON NEEDLE BIOPSY
Probably the most common use of immunohistochemistry (IHC) in the evaluation of the prostate is for the identification of basal cells, which are absent with rare exception in adenocarcinoma of the prostate (PCa). Although typically benign glands are positive for basal cells with IHC, adenosis, partial atrophy, and high-grade prostatic intraepithelial neoplasia (HGPIN) can have very patchy or absence of basal cells in a focus on needle biopsy (Figs. 1A–D). The most commonly used basal cell antibodies are high–molecular weight cytokeratin (HMWCK) (34βE12, cytokeratin [CK] 5/6)1–6 and p63,7–9 which are cytoplasmic and nuclear antibodies, respectively. p40 which is an isoform of p63 shows less aberrant p63 immunoreactivity in PCa but also has more nonspecific cytoplasmic staining compared with p63. In general p63 and p40 are comparable.10
Several studies comparing HMWCK and p63 have showed p63 to be slightly superior.7,8 One study demonstrated that CK5/6 was superior to 34βE12, although only a minority of pathologists use CK5/6.11 The use of a double cocktail combining HMWCK and p63 can increase the sensitivity of basal cell detection with a decrease in staining variability.12–14 There are uncommon cases of acinar adenocarcinoma that label positive with HMWCK and less so with p63 in a non–basal cell distribution. This phenomenon, although more commonly encountered in high-grade acinar adenocarcinoma (Gleason score of 8 to 10), has sometimes been reported in small foci of adenocarcinoma of Gleason pattern 3 on needle biopsies (Figs. 1E, F, 2A).15 Aberrant diffuse expression of p63 in acinar adenocarcinoma is a recently recognized phenomenon (Fig. 2B).15–17 These cases differ from those showing the nonspecific staining of basal cell markers in adenocarcinoma described above in 3 major aspects: (1) staining for p63 is strong and diffuse within the malignant glands; (2) the majority of cases with aberrant p63 show distinctive morphology of infiltrative glands, nests and cords with atrophic cytoplasm, hyperchromatic nuclei, and visible nucleoli; and (3) other basal cell markers such as 34βE12 and CK5/6 are totally negative.
α-Methylacyl-CoA-racemase (AMACR) is significantly upregulated in prostate cancer. Antibodies (P504S) have been developed against this protein.12,18–20 By IHC, the majority of prostate cancers are positive for AMACR, the sensitivity varying among studies from 82% to 100%.20–26 Two studies have shown that if a case is still considered atypical by a uropathology expert after negative basal cell staining, positive staining for AMACR can help establish in 50% of these cases a definitive diagnosis of cancer.27,28 There does not appear to be a difference between polyclonal and monoclonal P504s in the sensitivity of labeling prostate cancer.29
Different cocktails have been investigated combining antibodies for AMACR and basal cell–specific markers. One combination is with antibodies to p63 and AMACR, both labeled with a brown chromogen.30–32 Although authors have reported that this cocktail is essentially equal to each antibody used separately, in our experience a problem with this cocktail is that in some cases focal nuclear staining for p63 can be hard to detect if the cytoplasmic staining for AMACR is intensely positive. With small foci of atypical glands, the lesion may not survive sectioning to perform separate staining analyses for basal cell markers and AMACR on different slides.33 A triple-stain cocktail using a brown chromogen for both HMWCK and p63 and a red chromogen for AMACR optimizes the preservation of tissue for IHC and has been shown to be better than basal cell markers by themselves (Figs. 2C, D).34 In North America, there was a change in reimbursement for a triple stain containing 3 antibodies to the same as for 1 antibody, leading many laboratories that once used the triple stain to revert to 3 separate stains. Starting in January 2014, payers in the United States will revert to allowing payment for the 3 antibodies of a triple cocktail, although 2 antibodies will be compensated at a reduced rate. In cases in which there is no more tissue within the paraffin block and there are at least 2 hematoxylin and eosin (H&E) sections with the lesion, a technique has been developed to transfer tissue from one of the H&E slides to charged slides so that triple staining can be performed; an equivalent sensitivity compared with performing IHC off of the paraffin block can be achieved.35
The latest marker that has been proposed as an aid to the diagnosis of limited PCa is ERG. Fusions between the androgen-regulated transmembrane protease serine 2 gene (TMPRSS2) and the ERG gene are present in approximately 40% to 50% of PCas. This gene fusion is highly specific for prostate cancer, with the exception that 16% to 20% of HGPIN also shows the gene fusion. TMPRSS2-ERG gene fusion monoclonal anti-ERG antibodies are available, which correlate well with fusion-positive cancer. ERG antibodies have been shown to be negative in postatrophic hyperplasia, partial atrophy, and adenosis.36–38 Rare benign glands can express ERG.36,39 As an internal control, ERG labels endothelium. The major limitation of ERG as a diagnostic test is its low sensitivity, in that a negative stain does not exclude prostate carcinoma. Another weakness of this marker is that in 16% to 28% of cancers, there is heterogenous ERG expression, further contributing to false-negative staining on biopsy.40–43 In 16% to 20% of cases that are ERG positive, staining is also weak.40,44 Cocktails have also been developed for p63/ERG and ERG/AMACR/HMWCK/p63.40,44 There are conflicting studies on the diagnostic utility of ERG. Shah et al44 claimed that ERG helped establish a diagnosis of prostate cancer in 28% of cases that otherwise would have been diagnosed as “atypical, suspicious for carcinoma” using IHC for basal cell markers and AMACR. He et al,36 however, reported that ERG IHC was not discriminatory in helping to identify which “atypical foci” were likely to be associated with prostate cancer on rebiopsy. The advantages and disadvantages for the various antibodies for the diagnosis of limited PCa on needle biopsy are listed in Table 1.
Either HMWCK (34βE12 or CK5/6 or others) or p63 or a combination of the 2 with AMACR either in a double or triple cocktail is recommended for the workup of small foci of atypical glands suspicious for PCa. ERG is optional as it is present in only 40% to 50% of prostate cancers and also positive in HGPIN.
In the setting of obvious carcinoma, there is no justification to perform basal cell and AMACR staining.
In the setting of obviously benign glands, there is no justification to perform basal cell and AMACR staining.
WORKUP OF ATYPICAL FOCI WITH DEFINITE CANCER IN OTHER PARTS
Setting 1. Gleason score 3+4=7 or higher-grade cancer on at least 1 part: Workup of other parts with atypical foci suspicious for Gleason score 3+3=6 cancer.
Unlikely to change clinical treatment so not recommended.
Setting 2. Gleason score 4+3 or 4+4=8 cancer on at least 1 part: Workup other parts with atypical small foci suspicious for the same grade cancer.
The extent of high-grade cancer could affect clinical treatment such that workup of other atypical possible high-grade cancer foci is justified.
Setting 3. Gleason score 4+3 or higher-grade cancer on at least 1 part: Workup other parts for cribriform intraductal carcinoma versus diagnosing Gleason pattern 4 if doing so does not change the overall grade.
Given that intraductal carcinoma in the vast majority of cases is considered an extension of high-grade cancer into prostatic ducts and acini, it is not recommended in the setting of definitive invasive high-grade cancer that workup of additional cribriform lesions be pursued.
Setting 4. Gleason score 3+3 on at least 1 part: Workup other parts for possible small foci of 3+3=6.
The number of positive cores and/or their location could possibly affect subsequent therapy in terms of suitability for active surveillance or focal therapy, such that unless one knows with certainty that it would not affect therapy, it is justified to perform an IHC workup of additional atypical foci.
POORLY DIFFERENTIATED PCA VERSUS UROTHELIAL CARCINOMA
The distinction between poorly differentiated urothelial carcinoma and poorly differentiated PCa, even in a metastatic site, is critical, as the 2 are treated very differently. Although the distinction between urothelial carcinoma and PCa can usually be made on routinely stained sections, there may be overlap in cases in which PCa has marked pleomorphism and even pseudopapillary structures mimicking urothelial carcinoma. Consequently, in a poorly differentiated tumor involving the bladder and prostate without any glandular differentiation typical of PCa, the case should be worked up immunohistochemically.
With only a few exceptions, IHC staining for prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) is very specific for prostatic tissue. Situations that can cause diagnostic difficulty include PSA and PSAP within periurethral glands, as well as cystitis cystica and cystitis glandularis in both men and women.45,46 Other examples of cross-reactive staining include anal glands in men (PSA, PSAP) and urachal remnants (PSA).47,48 Some intestinal carcinoids and pancreatic islet cell tumors are strongly reactive with antibodies to PSAP, yet are negative with antibodies to PSA.49 Periurethral gland carcinomas in women and various salivary gland tumors may also be PSA and PSAP positive.50,51 Weak false-positive staining for PSAP has been reported in several breast and renal cell carcinomas, and we have seen some cases in which PSA was focally and weakly positive, although the patient was subsequently shown to have a nonprostatic tumor. This suggests that weak focal positive staining for either antigen should be interpreted with caution.
Although PSA and PSAP have proven to be useful in identifying prostate lineage, their sensitivity decreases in poorly differentiated PCa. In 3 studies addressing this issue, <25% of the tumor cells stained with PSAP and PSA in 35% to 70% and 25% to 50% of the cases, respectively.52–54 The same studies found 5% to 13% of cases to be completely negative to PSAP or PSA. The significance of these figures is that given the at times limited amount of tissue sampled, up to 50% of the PCa may be interpreted as negative for PSA or PSAP, owing to only focal positivity that may not be sampled. Even when both PSA and PSAP are used, the lack of immunoreactivity in a poorly differentiated tumor within the prostate, especially on a limited amount of sample, does not exclude the diagnosis of a poorly differentiated PCa. In such a scenario, newer prostate lineage markers such as prostein (P501S), prostate-specific membrane antigen (PSMA), NKX3.1, and androgen receptor could be of added utility (Figs. 3A–D).55–57 Of these markers, PSMA has lower specificity, and androgen receptor can also be positive in urothelial carcinoma. P501s has the benefit of distinctive clumpy granular immunoreactivity, and NKX3.1 is a very sensitive and specific nuclear antibody.
Combining some of the above markers with urothelial lineage markers will further facilitate resolving a urothelial versus prostatic carcinoma differential diagnosis. Studies have documented HMWCK positivity in >90% of urothelial carcinomas.56,58 HMWCK is only rarely and focally expressed in prostate carcinoma (8%).56 A cautionary note is warranted given that HMWCK labels squamous epithelia including areas of squamous differentiation in posttherapy recurrent prostate carcinoma lesions. HMWCK positivity that is restricted to areas of squamous differentiation does not exclude the diagnosis of PCa.59 P63 has a greater specificity albeit lower sensitivity for urothelial carcinoma compared with HMWCK (100% specificity and 83% sensitivity).56
Uroplakins are urothelium-specific transmembrane proteins expressed by the majority of noninvasive and up to two thirds of advanced invasive and metastatic urothelial carcinomas as assessed by UPIII.60–64 Although highly specific for urothelial differentiation, UPIII is only of moderate degree of sensitivity (as low as 40%) in high-grade urothelial carcinoma.65 Thrombomodulin is an endothelial cell–associated cofactor for thrombin-mediated activator of protein C. Its expression, predominantly as membranous staining, has been found in 69% to 100% of urothelial carcinomas.56,63,66 Thrombomodulin is only rarely positive in PCa.56,66 It is also expressed by nonurothelial tumors such as vascular tumors, mesotheliomas, and squamous cell carcinomas.66 Compared with UPIII, thrombomodulin has a higher degree of sensitivity but lower specificity as a marker for urothelial carcinoma. In a recent study, p63 was superior to thrombomodulin as a urothelial marker in high-grade tumors.56
GATA3 (GATA binding protein 3 to DNA sequence [A/T]GATA[A/G]) is a member of a zinc finger transcription factor family. Several recent studies have confirmed its utility as a marker for urothelial carcinoma.67–71 In the 2 largest studies by Liu et al69 and Miettinen et al,70 86% and >90% of urothelial carcinomas were positive for GATA3, respectively. The nuclear staining is usually diffuse in >50% of cells. In rare cases, PCas can be focally positive for GATA3.69–71 Finally, CK7 and CK20 are of limited utility in this differential given that they may both be positive in a subset of PCa.72,73
The various prostate and urothelial markers along with their advantages and disadvantages are listed in Tables 2 and 3.
Option to use PSA as a first test to identify PCa and GATA3 to identify UC.
If GATA3 is not available, then HMWCK and p63 can be used.
If the tumor is PSA positive with intense staining and HMWCK and p63 negative, the findings are diagnostic of PCa.
If the tumor is equivocal/weak/negative for PSA and negative/focal for p63 and HMWCK, then staining for P501S, NKX3.1, and GATA3 must be performed. Some experts also include PAP in this second round of staining.
If the tumor is negative for PSA and diffusely strongly positive for p63 and HMWCK, the findings are diagnostic of UC.
If the tumor is negative for PSA and moderately to strongly positive for GATA3, it is diagnostic of UC.
Laboratories should be encouraged to use GATA3 for UC and add P501S and NKX3.1 as prostate markers in addition to PSA, p63, and HMWCK.
If GATA3, p501S, and NKX3.1 are not available in equivocal cases, they should be sent out for consultation to laboratories with these antibodies.
HIGH-GRADE PCA VERSUS BLADDER ADENOCARCINOMA
In the differential diagnosis of bladder adenocarcinoma, one must first consider the possibility of secondary adenocarcinoma involving the bladder either by metastasis or direct invasion, such as from the prostate. Morphologically, there are differences in that bladder adenocarcinoma shares all of the various histologic patterns of adenocarcinoma arising in the gastrointestinal tract. However, if necessary, certain IHC stains can be utilized in the differential diagnosis with PCa. Monoclonal PSA antibodies do not label bladder adenocarcinoma, although polyclonal PSA and PSAP are positive in a significant percentage of bladder adenocarcinomas.74,75 Of the more recently discovered prostatic markers, PSMA lacks specificity but NKX3.1 and P501S do not react with bladder adenocarcinomas.56,76 The advantages and disadvantages of these and other antibodies are listed in Table 4.
PSA (monoclonal antibody), PAP (monoclonal antibody), P501S, NKX3.1, villin, thrombomodulin, CDX2, monoclonal CEA.
PROSTATIC SMALL CELL CARCINOMA VERSUS HIGH-GRADE PCA
The diagnosis of small cell carcinoma of the prostate is reached on the basis of morphologic features similar to those found in small cell carcinomas of the lung as defined in the 1999 World Health Organization classification criteria of pulmonary neoplasms. Morphologic variations of small cell carcinoma include the intermediate cell type with slightly more open chromatin and visible small nucleoli, which can be difficult to distinguish from high-grade PCa. Further complicating the issue is that in approximately 50% of the cases, the tumors are mixed small cell carcinoma and PCa. In some cases the transition between the small cell and acinar components is abrupt, and in other cases the 2 components merge together. It is critical to identify a small cell component, as prostatic small cell carcinomas are treated with the same chemotherapy as is used in pulmonary small cell carcinomas, whereas advanced high-grade PCa is initially treated with hormonal therapy. Often IHC is utilized in equivocal cases. The advantages and disadvantages of the various antibodies used in this differential diagnosis are shown in Table 5.
Using IHC techniques, the small cell component is positive for 1 or more neuroendocrine (NE) markers (synaptophysin, chromogranin, CD56) in almost 90% of cases (Figs. 3E, F).84,85 PSA and other prostatic markers such as P501s are positive in about 17% to 25% of cases, although often very focally (Table 2).84,85 In 24% and 35% of cases, positivity is noted for p63 and HMWCK, markers typically negative in prostatic carcinoma.85 Studies have demonstrated TTF-1 expression in >50% of small cell carcinomas of the prostate, limiting its utility in distinguishing primary small cell carcinoma of the prostate from a metastasis from the lung.84–87
Given the high rate of occult metastases, clinically localized small cell prostate cancer is typically treated aggressively, often with multimodality therapy with chemotherapy and radiation similar to limited-stage small cell lung cancer. Metastatic small cell carcinoma of the prostate is treated with platinum-based combination chemotherapy with regimens similar to those used to treat small cell lung carcinoma.88–91 Some experts treat pure small cell carcinoma with chemotherapy alone, whereas others add androgen deprivation therapy, in cases in which could be important to exclude metastasis or local extension from other sites such as bladder. A technique that can distinguish small cell carcinoma of the prostate from other small cell carcinomas is documentation by fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction of a gene fusion between members of the ETS family of genes, in particular ERG (ETS-related gene) and TMPRSS2, found in approximately one half of the usual PCas.92 In a similar percentage of cases, small cell carcinoma of the prostate is positive for TMPRSS2-ERG gene fusion by FISH.93–98 Importantly, it should be noted that compared with usual acinar carcinoma harboring TMPRSS2-ERG rearrangements, small cell carcinoma with TMPRSS2-ERG rearrangement is not reliably positive for ERG protein by IHC, presumably because of lack of androgen receptor expression in small cell carcinoma.93 In addition, in the setting of standard treatment for castrate-resistant prostate cancer, ERG protein expression may not be present by IHC, requiring the use of FISH. According to one study, there is strong and diffuse membrane staining for CD44 in all prostatic NE small cell carcinomas, whereas in usual PCas, only rare positive scattered tumor cells are CD44 positive.99 However, current work by one of the authors has not substantiated this finding and has concluded that this antibody is not useful in the distinction of high-grade PCa from small cell carcinoma.
The diagnosis can be made on the H&E-stained sections in the absence of special stains.
In cases in which the routinely stained sections are equivocal, a combination of prostate markers, NE markers, TTF-1, and ki67 can be used. CD44 has in 1 study claimed to be positive in prostatic small cell carcinoma and negative in usual PCa. However, the results need to be verified.
It should be recognized that not all small cell carcinomas express NE markers. CD56 is the most sensitive, yet least specific. Synaptophysin has the best combination of sensitivity and specificity. Chromogranin is the most specific but is often negative or only shows rare positive cells.
METASTATIC CARCINOMA UNKNOWN PRIMARY: RULE OUT PCA
Given that there is a treatment for metastatic PCa that can provide symptomatic relief and in some cases increased survival, it is critical to determine whether a metastatic carcinoma is of prostatic origin. There are several antibodies that can be used for this purpose, listed in Table 6. See references for High-grade Prostatic Adenocarcinoma versus Bladder Adenocarcinoma and Poorly Differentiated Prostate Adenocarcinoma versus Urothelial Carcinoma in addition to the ones listed in this chapter.18,40,100–107 One must also be aware that immunoreactivity for PSA and PSAP decreases after androgen deprivation therapy.108
PSA, PAP, prostein, NKX3.1.
NONSPECIFIC GRANULOMATOUS PROSTATITIS/XANTHOMA VERSUS HIGH-GRADE PCA
One of the principal entities that can be confused with high-grade prostate cancer is nonspecific granulomatous prostatitis (NSGP). Although most cases of NSGP seen on needle biopsy do not histologically resemble prostate cancer, 4% of cases can closely resemble cancer. These cases of NSGP consist of sheets of epithelioid histiocytes, some with prominent nucleoli with abundant granular cytoplasm.109 Xanthomas of the prostate can similarly mimic high-grade PCa.110 If there are difficulties in distinguishing NSGP from poorly differentiated adenocarcinoma, IHC can be utilized (Table 7).
Keratins (AE1/AE3, CAM5.2), CD68.
ADULT PROSTATE SARCOMA (STROMAL SARCOMA/LEIOMYOSARCOMA) VERSUS SARCOMATOID PCA
The differential diagnosis of a malignant spindle cell tumor in the prostate is sarcomatoid PCa (carcinosarcoma) versus a sarcoma. The most common sarcomas in the prostate in an adult are stromal sarcoma and leiomyosarcoma. Morphologically, leiomyosarcoma has a distinctive fascicular growth pattern that can be distinguished from a sarcomatoid carcinoma. A pitfall is the expression of keratin in some prostate leiomyosarcomas with conflicting studies on the presence of p63 in these tumors. More problematic is the distinction between a stromal sarcoma of the prostate and sarcomatoid PCa (Table 8).111–118
Desmin, PanCK, HMWCK, p63, CD34 (if stromal sarcoma in the differential).
COLORECTAL ADENOCARCINOMA VERSUS HIGH-GRADE PCA
Colorectal adenocarcinomas may also directly invade the prostate. Usually colorectal adenocarcinomas that invade the prostate are not occult, although occasionally they may present in the prostate. Adenocarcinoma of the rectum infiltrating the prostate may resemble one of the patterns of prostatic duct adenocarcinomas. Histologic features favoring colorectal adenocarcinoma are prominent desmoplasia, “dirty necrosis,” chronic inflammatory response, tall columnar epithelium with mucin, or mucin-positive signet ring cells. If there is difficulty in distinguishing colorectal adenocarcinoma from PCa, IHC is useful (Figs. 4A, B and Table 9).77,119–125
Prostate markers, CDX2, villin, β-catenin.
PROGNOSTIC IHC MARKERS
There have been multiple IHC markers that have been proposed for prognostic purposes. The more promising ones that have been studied to a greater extent are listed in Table 10.126–140 A limitation of all of them is that they have not been validated in prospective studies.
Currently, there are no prognostic IHC or molecular studies that are recommended to be routinely performed on biopsy or resection specimens.
1. Goldstein NS, Underhill J, Roszka J, et al..Cytokeratin 34 beta E-12 immunoreactivity in benign prostatic acini. Quantitation, pattern assessment, and electron microscopic study.Am J Clin Pathol.1999;112:69–74.
2. Brawer MK, Peehl DM, Stamey TA, et al..Keratin immunoreactivity in the benign and neoplastic human prostate.Cancer Res.1985;45:3663–3667.
3. Hedrick L, Epstein JI.Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.Am J Surg Pathol.1989;13:389–396.
4. O’Malley FP, Grignon DJ, Shum DT.Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland.Virchows Arch A Pathol Anat Histopathol.1990;417:191–196.
5. Shah IA, Schlageter MO, Stinnett P, et al..Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate.Mod Pathol.1991;4:220–224.
6. Wojno KJ, Epstein JI.The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.Am J Surg Pathol.1995;19:251–260.
7. Shah RB, Zhou M, LeBlanc M, et al..Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.Am J Surg Pathol.2002;26:1161–1168.
8. Weinstein MH, Signoretti S, Loda M.Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.Mod Pathol.2002;15:1302–1308.
9. Parsons JK, Gage WR, Nelson WG, et al..p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.Urology.2001;58:619–624.
10. Sailer V, Stephan C, Wernert N, et al..Comparison of p40 (DeltaNp63) and p63 expression in prostate tissues—which one is the superior diagnostic marker for basal cells?Histopathology.2013;63:50–56.
11. Abrahams NA, Ormsby AH, Brainard J.Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies.Histopathology.2002;41:35–41.
12. Rubin MA, Zhou M, Dhanasekaran SM, et al..alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.JAMA.2002;287:1662–1670.
13. Shah RB, Kunju LP, Shen R, et al..Usefulness of basal cell cocktail (34betaE12+p63) in the diagnosis of atypical prostate glandular proliferations.Am J Clin Pathol.2004;122:517–523.
14. Zhou M, Shah R, Shen R, et al..Basal cell cocktail (34betaE12+p63) improves the detection of prostate basal cells.Am J Surg Pathol.2003;27:365–371.
15. Brimo F, Epstein JI.Immunohistochemical pitfalls in prostate pathology.Hum Pathol.2012;43:313–324.
16. Osunkoya AO, Hansel DE, Sun X, et al..Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.Am J Surg Pathol.2008;32:461–467.
17. Giannico GA, Ross HM, Lotan T, et al..Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study.Am J Surg Pathol.2013;37:1401–1406.
18. Zhou M, Chinnaiyan AM, Kleer CG, et al..Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.Am J Surg Pathol.2002;26:926–931.
19. Luo J, Zha S, Gage WR, et al..Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.Cancer Res.2002;62:2220–2226.
20. Jiang Z, Woda BA, Rock KL, et al..P504S: a new molecular marker for the detection of prostate carcinoma.Am J Surg Pathol.2001;25:1397–1404.
21. Jiang Z, Wu CL, Woda BA, et al..P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.Am J Surg Pathol.2002;26:1169–1174.
22. Jiang Z, Wu CL, Woda BA, et al..Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.Histopathology.2004;45:218–225.
23. Beach R, Gown AM, De Peralta-Venturina MN, et al..P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.Am J Surg Pathol.2002;26:1588–1596.
24. Magi-Galluzzi C, Luo J, Isaacs WB, et al..Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.Am J Surg Pathol.2003;27:1128–1133.
25. Zhou M, Jiang Z, Epstein JI.Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.Am J Surg Pathol.2003;27:772–778.
26. Kunju LP, Rubin MA, Chinnaiyan AM, et al..Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.Am J Clin Pathol.2003;120:737–745.
27. Jiang Z, Iczkowski KA, Woda BA, et al..P504S immunostaining boosts diagnostic resolution of “suspicious” foci in prostatic needle biopsy specimens.Am J Clin Pathol.2004;121:99–107.
28. Zhou M, Aydin H, Kanane H, et al..How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?Am J Surg Pathol.2004;28:239–243.
29. Kunju LP, Chinnaiyan AM, Shah RB.Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.Histopathology.2005;47:587–596.
30. Molinie V, Fromont G, Sibony M, et al..Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate.Mod Pathol.2004;17:1180–1190.
31. Hameed O, Sublett J, Humphrey PA.Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.Am J Surg Pathol.2005;29:579–587.
32. Sanderson SO, Sebo TJ, Murphy LM, et al..An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays.Am J Clin Pathol.2004;121:220–225.
33. Browne TJ, Hirsch MS, Brodsky G, et al..Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.Hum Pathol.2004;35:1462–1468.
34. Jiang Z, Li C, Fischer A, et al..Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens.Am J Clin Pathol.2005;123:231–236.
35. Hameed O, Humphrey PA.p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning.Am J Clin Pathol.2005;124:708–715.
36. He H, Magi-Galluzzi C, Li J, et al..The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with “atypical glands suspicious for cancer”.Am J Surg Pathol.2011;35:608–614.
37. Green WM, Hicks JL, De Marzo A, et al..Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.Hum Pathol.2013;44:1895–1901.
38. Cheng L, Davidson DD, Maclennan GT, et al..Atypical adenomatous hyperplasia of prostate lacks TMPRSS2-ERG gene fusion.Am J Surg Pathol.2013;37:1550–1554.
39. Tomlins SA, Palanisamy N, Siddiqui J, et al..Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.Arch Pathol Lab Med.2012;136:935–946.
40. Yaskiv O, Zhang X, Simmerman K, et al..The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.Am J Surg Pathol.2011;35:1062–1068.
41. Minner S, Gartner M, Freudenthaler F, et al..Marked heterogeneity of ERG expression in large primary prostate cancers.Mod Pathol.2013;26:106–116.
42. Mertz KD, Horcic M, Hailemariam S, et al..Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer.Hum Pathol.2014;44:2727–2735.
43. Mosquera JM, Mehra R, Regan MM, et al..Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.Clin Cancer Res.2009;15:4706–4711.
44. Shah RB, Tadros Y, Brummell B, et al..The diagnostic use of ERG in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies beyond that provided by basal cell and alpha-methylacyl-CoA-racemase markers.Hum Pathol.2013;44:786–794.
45. Pollen JJ, Dreilinger A.Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands.Urology.1984;23:303–304.
46. Nowels K, Kent E, Rinsho K, et al..Prostate specific antigen and acid phosphatase-reactive cells in cystitis cystica and glandularis.Arch Pathol Lab Med.1988;112:734–737.
47. Golz R, Schubert GE.Prostatic specific antigen: immunoreactivity in urachal remnants.J Urol.1989;141:1480–1482.
48. Kamoshida S, Tsutsumi Y.Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland.Hum Pathol.1990;21:1108–1111.
49. Sobin LH, Hjermstad BM, Sesterhenn IA, et al..Prostatic acid phosphatase activity in carcinoid tumors.Cancer.1986;58:136–138.
50. Spencer JR, Brodin AG, Ignatoff JM.Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts.J Urol.1990;143:122–125.
51. van Krieken JH.Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry.Am J Surg Pathol.1993;17:410–414.
52. Svanholm H.Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase.Acta Pathol Microbiol Immunol Scand.1986;94:7–12.
53. Ellis DW, Leffers S, Davies JS, et al..Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate.Am J Clin Pathol.1984;81:279–284.
54. Ford TF, Butcher DN, Masters JR, et al..Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice.Br J Urol.1985;57:50–55.
55. Downes MR, Torlakovic EE, Aldaoud N, et al..Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.J Clin Pathol.2013;66:779–786.
56. Chuang AY, DeMarzo AM, Veltri RW, et al..Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.Am J Surg Pathol.2007;31:1246–1255.
57. Miyamoto H, Yao JL, Chaux A, et al..Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.BJU Int.2012;109:1716–1726.
58. Varma M, Morgan M, Amin MB, et al..High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer.Histopathology.2003;42:167–172.
59. Parwani AV, Kronz JD, Genega EM, et al..Prostate carcinoma with squamous differentiation: an analysis of 33 cases.Am J Surg Pathol.2004;28:651–657.
60. Huang HY, Shariat SF, Sun TT, et al..Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome.Hum Pathol.2007;38:1703–1713.
61. Kaufmann O, Volmerig J, Dietel M.Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas.Am J Clin Pathol.2000;113:683–687.
62. Moll R, Wu XR, Lin JH, et al..Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas.Am J Pathol.1995;147:1383–1397.
63. Parker DC, Folpe AL, Bell J, et al..Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.Am J Surg Pathol.2003;27:1–10.
64. Ohtsuka Y, Kawakami S, Fujii Y, et al..Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.BJU Int.2006;97:1322–1326.
65. Logani S, Oliva E, Amin MB, et al..Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.Am J Surg Pathol.2003;27:1434–1441.
66. Ordonez NG.Thrombomodulin expression in transitional cell carcinoma.Am J Clin Pathol.1998;110:385–390.
67. Esheba GE, Longacre TA, Atkins KA, et al..Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.Am J Surg Pathol.2009;33:347–353.
68. Higgins JP, Kaygusuz G, Wang L, et al..Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.Am J Surg Pathol.2007;31:673–680.
69. Liu H, Shi J, Wilkerson ML, et al..Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.Am J Clin Pathol.2012;138:57–64.
70. Miettinen M, McCue PA, Sarlomo-Rikala M, et al..GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.Am J Surg Pathol.2014;38:13–22.
71. Chang A, Amin A, Gabrielson E, et al..Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.Am J Surg Pathol.2012;36:1472–1476.
72. Genega EM, Hutchinson B, Reuter VE, et al..Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.Mod Pathol.2000;13:1186–1191.
73. Mhawech P, Uchida T, Pelte MF.Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.Hum Pathol.2002;33:1136–1140.
74. Grignon DJ, Ro JY, Ayala AG, et al..Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases.Cancer.1991;67:2165–2172.
75. Epstein JI, Kuhajda FP, Lieberman PH.Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder.Hum Pathol.1986;17:939–942.
76. Lane Z, Hansel DE, Epstein JI.Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.Am J Surg Pathol.2008;32:1322–1326.
77. Goldstein NS.Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores.Am J Clin Pathol.2002;117:471–477.
78. Torenbeek R, Lagendijk JH, Van Diest PJ, et al..Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma.Histopathology.1998;32:20–27.
79. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al..Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique.Histopathology.2007;50:472–483.
80. Suh N, Yang XJ, Tretiakova MS, et al..Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.Mod Pathol.2005;18:1217–1222.
81. Wang HL, Lu DW, Yerian LM, et al..Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.Am J Surg Pathol.2001;25:1380–1387.
82. Herawi M, De Marzo AM, Kristiansen G, et al..Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.Hum Pathol.2007;38:72–78.
83. Loy TS, Quesenberry JT, Sharp SC.Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases.Am J Clin Pathol.1992;98:175–179.
84. Wang W, Epstein JI.Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.Am J Surg Pathol.2008;32:65–71.
85. Yao JL, Madeb R, Bourne P, et al..Small cell carcinoma of the prostate: an immunohistochemical study.Am J Surg Pathol.2006;30:705–712.
86. Agoff SN, Lamps LW, Philip AT, et al..Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.Mod Pathol.2000;13:238–242.
87. Ordonez NG.Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas.Am J Surg Pathol.2000;24:1217–1223.
88. Amato RJ, Logothetis CJ, Hallinan R, et al..Chemotherapy for small cell carcinoma of prostatic origin.J Urol.1992;147:935–937.
89. Rubenstein JH, Katin MJ, Mangano MM, et al..Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy.Am J Clin Oncol.1997;20:376–380.
90. Aparicio AM, Harzstark AL, Corn PG, et al..Platinum-based chemotherapy for variant castrate-resistant prostate cancer.Clin Cancer Res.2013;19:3621–3630.
91. Papandreou CN, Daliani DD, Thall PF, et al..Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.J Clin Oncol.2002;20:3072–3080.
92. Tomlins SA, Rhodes DR, Perner S, et al..Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.Science.2005;310:644–648.
93. Lotan TL, Gupta NS, Wang W, et al..ERG gene rearrangements are common in prostatic small cell carcinomas.Mod Pathol.2011;24:820–828.
94. Han B, Mehra R, Lonigro RJ, et al..Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.Mod Pathol.2009;22:1083–1093.
95. Guo CC, Dancer JY, Wang Y, et al..TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.Hum Pathol.2011;42:11–17.
96. Williamson SR, Zhang S, Yao JL, et al..ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.Mod Pathol.2011;24:1120–1127.
97. Scheble VJ, Braun M, Wilbertz T, et al..ERG rearrangement in small cell prostatic and lung cancer.Histopathology.2010;56:937–943.
98. Schelling LA, Williamson SR, Zhang S, et al..Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.Hum Pathol.2013;44:2227–2233.
99. Slater D.Carcinoid tumour of the prostate associated with inappropriate ACTH secretion.Br J Urol.1985;57:591–592.
100. Bodey B, Bodey B Jr, Kaiser HE.Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas.Anticancer Res.1997;17:2343–2346.
101. Fan CY, Wang J, Barnes EL.Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.Am J Surg Pathol.2000;24:579–586.
102. Gurel B, Ali TZ, Montgomery EA, et al..NKX3.1 as a marker of prostatic origin in metastatic tumors.Am J Surg Pathol.2010;34:1097–1105.
103. Miettinen M, Wang ZF, Paetau A, et al..ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.Am J Surg Pathol.2011;35:432–441.
104. Sheridan T, Herawi M, Epstein JI, et al..The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.Am J Surg Pathol.2007;31:1351–1355.
105. Tazawa K, Kurihara Y, Kamoshida S, et al..Localization of prostate-specific antigen-like immunoreactivity in human salivary gland and salivary gland tumors.Pathol Int.1999;49:500–505.
106. Yin M, Dhir R, Parwani AV.Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.Diagn Pathol.2007;2:41.
107. Humphrey PA.Table 14.17.Prostate Pathology.2003.Chicago:ASCP Press;285.
108. Paterson RF, Gleave ME, Jones EC, et al..Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy.Mol Urol.1999;3:277–286.
109. Oppenheimer JR, Kahane H, Epstein JI.Granulomatous prostatitis on needle biopsy.Arch Pathol Lab Med.1997;121:724–729.
110. Chuang AY, Epstein JI.Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma.Am J Surg Pathol.2007;31:1225–1230.
111. Cheville JC, Dundore PA, Nascimento AG, et al..Leiomyosarcoma of the prostate. Report of 23 cases.Cancer.1995;76:1422–1427.
112. Westfall DE, Folpe AL, Paner GP, et al..Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder.Am J Surg Pathol.2009;33:99–105.
113. Jo VY, Fletcher CD.P63 immunohistochemical staining is limited in soft tissue tumors.Am J Clin Pathol.2011;136:762–766.
114. Hansel DE, Herawi M, Montgomery E, et al..Spindle cell lesions of the adult prostate.Mod Pathol.2007;20:148–158.
115. Gaudin PB, Rosai J, Epstein JI.Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases.Am J Surg Pathol.1998;22:148–162.
116. Herawi M, Epstein JI.Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases.Am J Surg Pathol.2006;30:694–704.
117. Bostwick DG, Hossain D, Qian J, et al..Phyllodes tumor of the prostate: long-term followup study of 23 cases.J Urol.2004;172:894–899.
118. Dundore PA, Cheville JC, Nascimento AG, et al..Carcinosarcoma of the prostate. Report of 21 cases.Cancer.1995;76:1035–1042.
119. Osunkoya AO, Netto GJ, Epstein JI.Colorectal adenocarcinoma involving the prostate: report of 9 cases.Hum Pathol.2007;38:1836–1841.
120. Owens CL, Epstein JI, Netto GJ.Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry.Arch Pathol Lab Med.2007;131:599–603.
121. Contreras HR, Ledezma RA, Vergara J, et al..The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.Urol Oncol.2010;28:534–540.
122. Fiorentino M, Zadra G, Palescandolo E, et al..Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.Lab Invest.2008;88:1340–1348.
123. Jaggi M, Johansson SL, Baker JJ, et al..Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.Urol Oncol.2005;23:402–406.
124. Lazari P, Poulias H, Gakiopoulou H, et al..Differential immunohistochemical expression of CD44s, E-cadherin and beta-catenin among hyperplastic and neoplastic lesions of the prostate gland.Urol Int.2013;90:109–116.
125. Whitaker HC, Girling J, Warren AY, et al..Alterations in beta-catenin expression and localization in prostate cancer.Prostate.2008;68:1196–1205.
126. Aslan G, Irer B, Tuna B, et al..Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.Pathol Res Pract.2006;202:93–98.
127. Bauer JJ, Sesterhenn IA, Mostofi FK, et al..Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.J Urol.1996;156:1511–1516.
128. Bauer JJ, Sesterhenn IA, Mostofi KF, et al..P53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.Clin Cancer Res.1995;1:1295–1300.
129. Bethel CR, Faith D, Li X, et al..Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion.Cancer Res.2006;66:10683–10690.
130. Brewster SF, Oxley JD, Trivella M, et al..Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.J Urol.1999;161:1238–1243.
131. Cheng L, Pisansky TM, Sebo TJ, et al..Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.Clin Cancer Res.1999;5:2820–2823.
132. Gurel B, Iwata T, Koh CM, et al..Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.Mod Pathol.2008;21:1156–1167.
133. Gurel B, Iwata T, Koh CM, et al..Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.Adv Anat Pathol.2008;15:319–331.
134. Kuczyk MA, Serth J, Bokemeyer C, et al..The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy.Eur J Cancer.1998;34:679–686.
135. Lotan TL, Gurel B, Sutcliffe S, et al..PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.Clin Cancer Res.2011;17:6563–6573.
136. Moul JW, Bettencourt MC, Sesterhenn IA, et al..Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.Surgery.1996;120:159–166discussion 166–167.
137. Sarker D, Reid AH, Yap TA, et al..Targeting the PI3K/AKT pathway for the treatment of prostate cancer.Clin Cancer Res.2009;15:4799–4805.
138. Stapleton AM, Zbell P, Kattan MW, et al..Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.Cancer.1998;82:168–175.
139. Theodorescu D, Broder SR, Boyd JC, et al..P53, Bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.J Urol.1997;158:131–137.
140. Vis AN, van Rhijn BW, Noordzij MA, et al..Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.J Pathol.2002;197:148–154.
ISUP recommendations; immunohistochemistry; best practices; prostate; atypical small acinar proliferation; small cell carcinoma; metastatic carcinoma; prostatic sarcoma; racemase; p63
© 2014 by Lippincott Williams & Wilkins.
Highlight selected keywords in the article text.